Best Overall Response (PRISSMM Criteria)						
	Cohort 1 (n 34)		Cohort 2 (n 48)		Cohort 3 (n 127)	
	First CDK4/6i exposure	CDK4/6i retreatment	First CDK4/6i exposure	CDK4/6i retreatment	First CDK4/6i exposure	CDK4/6i retreatment
Disease Progression	0	5 (15%)	14 (29.1%)	23 (47.9%)	39 (30.7%)	52 (40.9%)
Stable Disease	10 (29%)	10 (29%)	6 (12.5%)	12 (25%)	30 (23.6%)	31 (24.4%)
Radiological Benefit	11 (32%)	10 (29%)	25 (52.0%)	7 (14.5%)	54 (42.5%)	28 (22.0%)
Non-evaluable (Treatment changed before first re-staging image)	13 (38%)	9 (26%)	3 (6.2%)	6 (12.5%)	4 (3.1%)	16 (12.6%)

Supplementary Table 1: Best Overall Response by Cohort

Best overall response by radiographic PRISSMM criteria is outlined by cohort in the table

above. Patients that were nonevaluable were mainly patients that did not get radiographic

imaging to determine disease state prior to changing therapies.